Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Assessment of Frailty Measures and Their Effect on Survival in a Population of Patients Registered At Marche Region Multiple Myeloma (MM) Registry

Massimo Offidani, MD, Claudia Polloni, Laura Corvatta, Riccardo Centurioni, MD, Giuseppe Visani, Marino Brunori, Silvia Gentili, Massimo Catarini, Arduino Samori, Nicola Blasi, Francesco Alesiani, Patrizia Caraffa, Maurizio Burattini, Piero Galieni, Paolo Fraticelli, Mario Ferranti, Luciano Giuliodori, Pietro Leoni

Blood (2011) 118 (21): 2873.

https://doi.org/10.1182/blood.V118.21.2873.2873

Published: 2011

Journal Articles

Multicentric prospective Study of Differential Treatment for Elderly Patients Affected by Aggressive Non Hodgkin Lymphoma Based On a Geriatric Multidimensional Analysis.

Guido Gini, Attilio Olivieri, MD, Caterina Bocci, Massimo Catarini, Giuseppe Visani, Mauro Montanari, M.D., Barbara Guiducci, Alessandro Isidori, MD, PhD, Marino Brunori, Francesco Alesiani, Luciano Giuliodori, Massimo Marcellini, Massimo Offidani, MD, Patrizia Caraffa, Andrea Stronati, Debora Capelli, Silvia Trappolini, Pietro Leoni

Blood (2009) 114 (22): 4775.

https://doi.org/10.1182/blood.V114.22.4775.4775

Published: 2009

Journal Articles

ThaDD Regimen for Patients with Multiple Myeloma Aged ≥ 65 Years: An Update of the First 50 Patients Enrolled

Blood (2008) 112 (11): 5186.

https://doi.org/10.1182/blood.V112.11.5186.5186

Published: 2008

Journal Articles

Safety and Efficacy of ThaDD Regimen in Very Elderly Patients with Multiple Myeloma (MM)

Massimo Offidani, MD, Laura Corvatta, Maria-Novella Piersantelli, Claudia Polloni, Silvia Gentili, Piero Galieni, Giuseppe Visani, Francesco Alesiani, Massimo Catarini, Marino Brunori, Arduino Samori, Maurizio Burattini, Riccardo Centurioni, Mario Ferranti, Luciano Giuliodori, Marco Candela, Monica Marconi, Anna Mele, Pietro Leoni

Blood (2008) 112 (11): 5196.

https://doi.org/10.1182/blood.V112.11.5196.5196

Published: 2008

Journal Articles

Thalidomide-Dexamethasone vs Interferon-α-Dexamethasone as Maintenance Treatment after ThaDD Induction for Multiple Myeloma (MM): Final Analysis of a Prospective, Randomized Study.

Massimo Offidani, MD, Claudia Polloni, MD, Laura Corvatta, MD, Maria-Novella Piersantelli, MD, Piero Galieni, MD, Giuseppe Visani, MD, Francesco Alesiani, MD, Massimo Catarini, MD, Marino Brunori, MD, Maurizio Burattini, MD, Riccardo Centurioni, MD, Mario Ferranti, MD, Luciano Giuliodori, MD, Marco Candela, MD, Anna Mele, MD, Monica Marconi, MD, Pietro Leoni, PhD

Blood (2007) 110 (11): 532.

https://doi.org/10.1182/blood.V110.11.532.532

Published: 2007

Journal Articles

Thalidomide-Dexamethasone (Thal-dex) vs Interferon-α-Dexamethasone (IFN-dex) as Maintenance Treatment after ThaDD Induction for Multiple Myeloma (MM): First Analysis of a Prospective Randomized Study.

Massimo Offidani, MD, Laura Corvatta, MD, Claudia Polloni, MD, Maria-Novella Piersantelli, MD, Piero Galieni, MD, Giuseppe Visani, MD, Francesco Alesiani, MD, Massimo Catarini, MD, Marino Brunori, MD, Maurizio Burattini, MD, Riccardo Centurioni, MD, Mario Ferranti, MD, Luciano Giuliodori, MD, Marco Candela, MD, Monica Marconi, MD, Pietro Leoni, PhD

Blood (2006) 108 (11): 3566.

https://doi.org/10.1182/blood.V108.11.3566.3566

Published: 2006

Journal Articles

Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma

Blood (2006) 108 (7): 2159–2164.

https://doi.org/10.1182/blood-2006-03-013086

Published: 2006

Journal Articles

Thalidomide, Dexamethasone and Pegylated-Liposomal Doxorubicin (ThaDD) for Untreated Multiple Myeloma Patients Aged over 65 Years.

Massimo Offidani, MD, Laura Corvatta, MD, Monica Marconi, MD, Giuseppe Visani, MD, Francesco Alesiani, MD, Marino Brunori, MD, Piero Galieni, MD, Massimo Catarini, MD, Maurizio Burattini, MD, Riccardo Centurioni, MD, Serena Rupoli, MD, Anna Rita Scortechini, MD, Luciano Giuliodori, MD, Marco Candela, MD, Debora Capelli, MD, Mauro Montanari, MD, Attilio Olivieri, Ph. D., Maria-Novella Piersantelli, MD, Pietro Leoni, Ph. D.

Blood (2005) 106 (11): 2558.

https://doi.org/10.1182/blood.V106.11.2558.2558

Published: 2005

NARROW

Assessment of Frailty Measures and Their Effect on Survival in a Population of Patients Registered At Marche Region Multiple Myeloma (MM) Registry

Multicentric prospective Study of Differential Treatment for Elderly Patients Affected by Aggressive Non Hodgkin Lymphoma Based On a Geriatric Multidimensional Analysis.

ThaDD Regimen for Patients with Multiple Myeloma Aged ≥ 65 Years: An Update of the First 50 Patients Enrolled

Safety and Efficacy of ThaDD Regimen in Very Elderly Patients with Multiple Myeloma (MM)

Thalidomide-Dexamethasone vs Interferon-α-Dexamethasone as Maintenance Treatment after ThaDD Induction for Multiple Myeloma (MM): Final Analysis of a Prospective, Randomized Study.

Thalidomide-Dexamethasone (Thal-dex) vs Interferon-α-Dexamethasone (IFN-dex) as Maintenance Treatment after ThaDD Induction for Multiple Myeloma (MM): First Analysis of a Prospective Randomized Study.

Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma

Thalidomide, Dexamethasone and Pegylated-Liposomal Doxorubicin (ThaDD) for Untreated Multiple Myeloma Patients Aged over 65 Years.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only